AI/Machine Learning: Regulation, Development, and Real-World Performance Evaluation
Webinar | 03.22.22, 12:30 PM UTC - 4:00 PM UTC
On March 22, 2022 from 12:30 – 4:00 pm (EDT) the Duke-Margolis Center of Health Policy, with participation from the U.S. Food and Drug Administration (FDA) speakers and panelists, will hold a public webinar to spotlight updates and progress made since the release of FDA’s Artificial Intelligence/Machine Learning Action Plan in early 2021.
There will be a fireside chat between Jeff Shuren, FDA’s director of the Center for Devices and Radiological Health (CRDH), and Mark McClellan, director of Duke-Margolis, followed by three panel discussions focused on the following topics:
- Overarching frameworks for regulating and evaluating AI
- Good machine learning practices (GMLP)
- Post-market evaluation of AI/ML SaMD
The webinar will end with a business roundtable discussion on how developers and health care systems are considering these issues.
For more information, please visit these areas: Artificial Intelligence
Participants
Partner & CHS Managing Director
She/Her/Hers
Insights
Webinar | 06.11.25
Section 230: Implications for Digital Platforms, Online Businesses and E-Commerce
Section 230 was enacted as part of the United States Communications Decency Act (CDA), providing immunity to interactive computer service providers for third-party content. Known as “the 26 words that created the internet,” this statute is responsible for the development of the modern internet as we know it.
Webinar | 05.13.25
